These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22025648)

  • 1. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.
    Gamble JM; Weir DL; Johnson JA; Eurich DT
    CMAJ; 2011 Nov; 183(17):E1259-66. PubMed ID: 22025648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance.
    Milliken D; Venkatesh J; Yu R; Su Z; Thompson M; Eurich D
    BMJ Open; 2015 Sep; 5(9):e008100. PubMed ID: 26341583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.
    Gamble JM; Eurich DT; Johnson JA
    Healthc Policy; 2010 Nov; 6(2):e117-44. PubMed ID: 22043227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
    Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
    Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
    Allen N; Walker SR; Liberti L; Sehgal C; Salek MS
    CMAJ Open; 2016; 4(4):E674-E678. PubMed ID: 28018881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How many physicians does Canada need to care for our aging population?
    Roos NP; Bradley JE; Fransoo R; Shanahan M
    CMAJ; 1998 May; 158(10):1275-84. PubMed ID: 9614820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity among health care leaders in Canada: a cross-sectional study of perceived gender and race.
    Sergeant A; Saha S; Lalwani A; Sergeant A; McNair A; Larrazabal E; Yang K; Bogler O; Dhoot A; Werb D; Maghsoudi N; Richardson L; Hawker G; Siddiqi A; Verma A; Razak F
    CMAJ; 2022 Mar; 194(10):E371-E377. PubMed ID: 35288408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research to Action: an evaluation.
    Murphy GT; Alder R; MacKenzie A; Cook A; Maddalena V
    Nurs Leadersh (Tor Ont); 2012 Mar; 25 Spec No 2012():21-32. PubMed ID: 22398474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
    Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
    Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-Stage Cannabis Regulatory Policy Planning Across Canada's Four Largest Provinces: A Descriptive Overview.
    Watson TM; Hyshka E; Bonato S; Rueda S
    Subst Use Misuse; 2019; 54(10):1691-1704. PubMed ID: 31076006
    [No Abstract]   [Full Text] [Related]  

  • 19. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies.
    Gamble JM; McAlister FA; Johnson JA; Eurich DT
    Clin Ther; 2012 Jun; 34(6):1379-1386.e3. PubMed ID: 22554975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
    Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
    Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.